ClinicalTrials.gg
CompletedNCT02982889Updated Aug 24, 2017

Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations

A Phase 1 interventional study of LIQ865A bupivacaine formulation and LIQ865B bupivacaine formulation in Acute Pain, sponsored by Liquidia Technologies, Inc.. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-24.

Sponsored by Liquidia Technologies, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing bupivacaine in Acute Pain — 5 open to participants now, 5 under way, none of them phase 3. Bupivacaine · Acute Pain.

Enrollment
31st of 34
29 · median 74
Started
2016
with 2 others
Phase 1
2 of 34
none open now
Registered
7th of 34
by date

Among the 34 studies testing bupivacaine in Acute Pain, this one is the 31st largest by enrollment, is one of 3 that started in 2016, is one of 2 in phase 1, and was the 7th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

5 of the 34 studies testing bupivacaine in Acute Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing bupivacaine in Acute Pain, or all of them as a file.
02

Study summary

This study is designed to assess and characterize the safety and tolerability profile of LIQ865A and LIQ865B formulations compared to diluent or aqueous bupivacaine hydrochloride when infiltrated into a defined area of the medial calf, and to characterize bupivacaine plasma pharmacokinetic (PK) and pharmacodynamic (PD) profiles after a single dose of LIQ865A or LIQ865B, and to determine the individual plasma concentration/time curves and mean PK parameters of each product.

Read the detailed description

Infiltration of an aqueous local anesthetic, for example, bupivacaine, into surgical sites at closure provides temporary analgesia, typically lasting up to 6 hours, and is one aspect of the multimodal approach to postsurgical analgesia or fast-track surgery. However, the limited duration of action of local anesthetics, even longer acting agents such as bupivacaine, result in patients who are likely to experience end of duration breakthrough pain before they are able to take or tolerate oral analgesics, thus necessitating the use of strong parenteral analgesics in the immediate postsurgical period. LIQ865A and LIQ865B are two distinct formulations of bupivacaine manufactured via Liquidia Technologies PRINT (Particle Replication In Non-wetting Templates), which Liquidia intends to pursue for product approval. Both formulations being tested have the potential for producing long-lasting control of post-surgical incisional pain.

03

Conditions studied

  • Acute Pain

Keywords

  • Analytical, Diagnostic,Therapeutic Technique and Equipment
  • Anesthesia and Analgesia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • provide written prior to enrollment
  • be a non-smoking male, (ASA) physical class 1 or 2
  • have a between 18.5 and 25 kg. inclusive, and a weight of at least 60 kg
  • be willing and able to participate for the duration of the study
  • be healthy on the basis of pre-study physical examination (PE), medical history review, vital signs, lab test results as specified in the protocol
  • negative urine drug test results
  • negative alcohol screening test
  • negative antibody test results for , , and

Exclusion criteria

Exclusion Criteria:

  • allergic to bupivacaine, or other amide local anesthetics, or the in the LIQ865 formulations or the diluent
  • has taken any concomitant medications or supplements for the 3 days prior to Day 0
  • has been on blood thinner or medication affecting formation for the 7 days prior to Day 0
  • in the opinion of the investigator, is either a hyper or hypo-responder to screening sensitivity testing
  • has a history of moderate or severe renal or hepatic impairment, moderate or severe active hepatic disease, or any other medical condition that may preclude safe study participation
  • has a clinically significant test result for any screening lab parameter
  • has a history or screening documentation of a clinically meaningful conduction abnormality
  • has scarring, tattoos, infections, or other skin changes in the area of planned study medication injection
  • has known neurological disease or dysfunction (central or peripheral) that may interfere with assessments
  • is unable to adequately communicate with study staff, properly give , or otherwise comply with study procedures, particularly the ability to return for outpatient follow up visits
  • has participated in another interventional clinical study ( or marketed product) within the 30 days prior to Day 0.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    LIQ865A bupivacaine formulation

    Liquidia's PRINT bupivacaine free base/PLGA (poly D,L-lactic-co-glycolic acid) suspension for subcutaneous injection at doses ranging from 150mg to 600mg

    Drug: LIQ865A bupivacaine formulation · Drug: Diluent for LIQ865

  • Experimental
    LIQ865B bupivacaine formulation

    Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg

    Drug: LIQ865B bupivacaine formulation · Drug: Diluent for LIQ865

  • Placebo comparator
    Diluent for LIQ865

    Negative control for subcutaneous injection. Each subject will act as his own control, receiving a LIQ865 formulation subcutaneous injection in one calf, and a diluent subcutaneous injection in his other calf

    Drug: LIQ865A bupivacaine formulation · Drug: LIQ865B bupivacaine formulation · Drug: Diluent for LIQ865

  • Active comparator
    0.5% bupivacaine hydrochoride

    Positive control arm to be used with one of the LIQ865 cohorts, with each subject acting as his own positive control (i.e., one leg will receive subcutaneous injection of LIQ865A or LIQ865B, and the other leg will receive subcutaneous injection of 0.5% bupivacaine hydrochloride).

    Drug: LIQ865A bupivacaine formulation · Drug: LIQ865B bupivacaine formulation · Drug: 0.5% bupivacaine hydrochoride

Interventions

  • single subcutaneous injection in medial calf

    Also known as: Marcaine, Marcaine Spinal, Sensorcaine, Sensorcaine-MPF, Sensorcaine-MPF Spinal, Marcaine HCl, Exparel

  • single subcutaneous injection in medial calf

    Also known as: Marcaine, Marcaine Spinal, Sensorcaine, Sensorcaine-MPF, Sensorcaine-MPF Spinal, Marcaine HCl, Exparel

  • Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection

    Also known as: Hyaluronic Acid

  • single subcutaneous injection

    Also known as: Marcaine, Marcaine Spinal, Sensorcaine, Sensorcaine-MPF, Sensorcaine-MPF Spinal, Marcaine HCl, Exparel

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (AEs)

    Safety assessments will include the incidence and severity of AEs during treatment and the follow-up period of the study

    Time frame: 30 days

Secondary outcomes

  1. Pharmacokinetic - Area under the plasma concentration curve from time zero to Day 5

    Time frame: Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment

  2. Pharmacokinetic - Cmax (ng/mL)

    Maximum plasma concentration over the entire sampling period, directly obtained from the experimental data of plasma concentration versus time curves, without interpolation.

    Time frame: Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment

  3. Pharmacokinetic - Tmax (h)

    Time to reach maximum plasma concentration

    Time frame: Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment

  4. Pharmacokinetic - t1/2 (h)

    Apparent terminal elimination half-life

    Time frame: Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment

  5. Pharmacokinetic - CST1/2 (h)

    Context-sensitive half-time measured from Tmax to time for plasma concentration to reach half of Cmax following study medication injection.

    Time frame: Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment

  6. Pharmacodynamic Response - Pain intensity (Numeric Rating Scale) with Short Tonic Heat Stimulus (STHS) testing at various time points

    Testing done to calculate time-weighted Sum of Pain Intensity Differences (SPID) at the time points noted, compared to Baseline, and time specific SPID results

    Time frame: 1, 2, 12, 24, 48, 72, 96, and 120 hours

  7. Pharmacodynamic Response - Change in Mechanical Pain Threshold (MPT) compared to Baseline using various time points

    Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120

    Time frame: 12, 24, 48, 72, 96, and 120 hours

  8. Pharmacodynamic Response - Change in Heat Pain Threshold (HPT) compared to Baseline using various time points

    Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120

    Time frame: 12, 24, 48, 72, 96, and 120 hours

  9. Pharmacodynamic Response - Change Mechanical Detection Threshold (MDT) compared to Baseline using various time points

    Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120

    Time frame: 12, 24, 48, 72, 96, and 120 hours

  10. Pharmacodynamic Response - Change in Warmth Detection Threshold (WDT) compared to Baseline using various time points

    Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120

    Time frame: 12, 24, 48, 72, 96, and 120 hours

  11. Pharmacodynamic Response - Change in Cold Detection Threshold (CDT) compared to Baseline using various time points

    Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120

    Time frame: 12, 24, 48, 72, 96, and 120 hours

07

Study locations

1 site
  • DanTrial Aps
    Copenhagen, 2400, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Mar 2017, 3 months.

Of 33 phase 1 interventional studies under Acute Pain, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 17. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Dec 6, 2016
StartActual
Dec 5, 2016
Primary completionActual
Mar 23, 2017
CompletionActual
Apr 26, 2017
Last update
Aug 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02982889
Lead sponsor
Liquidia Technologies, Inc.
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Dec 6, 2016
Start date
Dec 5, 2016
Primary completion
Mar 23, 2017
Completion
Apr 26, 2017
Last update
Aug 24, 2017

Study contacts

Mads U Werner, MD
principal investigator · Multidisciplinary Pain Center, Rigshospitalet

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Hyaluronic Acid

Start the discussion